Navigation Links
Northwestern nets NIH grant to tailor drugs to patients' genome

CHICAGO --- Northwestern University Feinberg School of Medicine researchers have received a $762,000 grant from the National Institutes of Health (NIH) to tailor drug treatments to patients' genomic information. The grant, provided to members of the Electronic Medical Records and Genomics (eMERGE) network, is from the National Human Genome Research Institute (NHGRI), part of the NIH, which supports research by the network's seven institutions and coordinating center.

"This new eMERGE grant is an important step in connecting genomic information to high-quality data in electronic medical records during the clinical care of patients, and Northwestern is proud to be at the forefront of this initiative," says Rex L. Chisholm, vice dean of scientific affairs and graduate education, the Adam and Richard T. Lind Professor of Medical Genetics and a professor in cell and molecular biology at the Center for Genetic Medicine and Surgery at the Feinberg School. "The ultimate goal is to identify the genetic contributions to disease and equip health centers with the information and tools needed to apply genomic knowledge to patient care."

The grant enables investigators to identify genetic variants associated with 40 more disease characteristics and symptoms, using genome-wide association studies across the entire eMERGE network. DNA from about 32,000 participants will be analyzed in each study. Genome-wide association studies represent a powerful approach researchers can use to study hundreds of thousands of genetic variants in people with and without certain health conditions to identify genes that cause or contribute to diseases.

eMERGE researchers will then use the genomic information in clinical care. With patient consent, researchers may use information about genetic variants involved in drug response to adjust patient medications. In addition, eMERGE researchers who discover patients harboring genetic variants associated with diseases such as diabetes or cardiovascular disease will intervene to prevent, diagnose and/or treat such diseases.

The first phase of eMERGE, which wrapped up in July, demonstrated that data about disease characteristics in electronic medical records and patients' genetic information can be used in large genetic studies. So far, the eMERGE network has identified genetic variants associated with dementia, cataracts, high-density lipoprotein (HDL) cholesterol, peripheral arterial disease, white blood cell count, type 2 diabetes and cardiac conduction defects.


Contact: Marla Paul
Northwestern University

Related biology news :

1. New dinosaur species possible in Northwestern Alberta
2. The fragility of the worlds coral is revealed through a study of the Northwestern Hawaiian Islands
3. ASHG awards $10,000 genetics education research grant to Maurice Godfrey of University of Nebraska
4. OU-led research team receives $1.28 million grant from DOE
5. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
6. MSU professor launches new field of water research, nets $2.2 million NSF grant
7. Lincoln Park Zoo awarded 2 significant grants for science education
8. $3 million grant to aid minorities with uncontrolled diabetes
9. The Guy Harvey Ocean Foundation awards research grant to RJ Dunlap Marine Conservation Program
10. CWRU receives $2.1 million NIH grant to expand cystic fibrosis research models
11. St. Josephs scientist receives grant for post-partum research
Post Your Comments:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology: